Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
ACS results from plaque rupture/erosion with downstream thrombosis causing supply‑demand mismatch and myocyte necrosis. Establish diagnosis with serial troponins and ECGs, recognize STEMI equivalents, and differentiate alternative causes of chest pain. Risk‑stratify NSTEMI/UA using validated tools (GRACE/TIMI) to guide invasive timing.
Treatment Strategy & Disposition
Initiate aspirin, anticoagulation, and anti‑ischemic therapy; add P2Y12 inhibitor when an early invasive strategy is planned. Address precipitating factors (tachyarrhythmias, anemia, hypertension) and optimize secondary prevention (statin, ACEi/ARB, β‑blocker). Select radial‑access PCI when feasible to reduce bleeding. Disposition is driven by hemodynamics, ischemic burden, and arrhythmia risk—ICU/telemetry for high‑risk patients.
Epidemiology / Risk Factors
- Atherosclerotic risk (HTN, DM, HLD, smoking)
- Age/family history of premature CAD
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| EKG | Rhythm/ischemia | ST-T changes/arrhythmia | Serial |
| Troponin | Myocardial injury | Dynamic rise/fall | Trend |
| CXR | Pulmonary edema/size | Cardiomegaly/edema | |
| BMP/Mg2+ | Electrolytes/renal | Derangements | |
| CBC/Coags | Bleeding risk | Abnormal/INR |
Antithrombotic Options (Initial)
| Class | Examples | Notes |
|---|---|---|
| Antiplatelet | Aspirin + P2Y12 (ticagrelor/prasugrel/clopidogrel) | Choice depends on PCI timing and bleeding risk |
| Anticoagulant | UFH, enoxaparin, fondaparinux | UFH preferred if early PCI or high bleeding risk control |
| Anti-ischemic | Nitrates, beta-blocker | Avoid beta-blocker in acute decompensated HF |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Aspirin | COX-1 inhibition (platelet) | Minutes | Immediate antiplatelet | GI bleed; allergy |
| P2Y12 inhibitor (ticagrelor/clopidogrel) | ADP receptor blockade | Hours | Dual antiplatelet with PCI/NSTEMI | Bleeding; dyspnea (ticagrelor) |
| High-intensity statin | HMG-CoA reductase inhibition | Days | Secondary prevention | Hepatotoxicity, myopathy |
| Nitroglycerin | Venodilation | Minutes | Anti-ischemic symptom relief | Hypotension; avoid with PDE5i or RV infarct |
| Heparin (UFH) | Antithrombin activation | Immediate | Anticoag during ACS/PCI | Bleeding, HIT |
Prognosis / Complications
- Prognosis by ischemic burden/LV function
- Arrhythmias and HF are complications
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Avoid routine oxygen if SpO2 ≥90%. Consider radial access PCI to reduce bleeding. Manage antithrombotics carefully in CKD and elderly.
References
Use the Library, QBank, CCS, and analytics in one study workflow.
You just reviewed Acute Coronary Syndrome — NSTEMI/Unstable Angina. MDSteps helps you turn that review into exam-style practice, missed-item flashcards, and a readiness dashboard that shows what to study next.
- 16,000+ USMLE-style questions across Step 1, Step 2, and Step 3
- CCS simulator with timed orders, live vitals, and case feedback
- Depth-on-Demand™ explanations and Anki-exportable flashcards
- Library + QBank + analytics for $27/month or $299 lifetime